# Mirikizumab in the Treatment of Chronic Inflammatory Conditions of the Pouch

> **NCT06864403** · PHASE4 · RECRUITING · sponsor: **University of North Carolina, Chapel Hill** · enrollment: 25 (estimated)

## Conditions studied

- Pouchitis
- Pouches, Ileoanal
- Pouch, Ileal

## Interventions

- **DRUG:** Mirikizumab - Intravenous (IV)
- **DRUG:** Mirikizumab - Subcutaneous (SC)

## Key facts

- **NCT ID:** NCT06864403
- **Lead sponsor:** University of North Carolina, Chapel Hill
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-12
- **Primary completion:** 2027-04
- **Final completion:** 2027-04
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2026-01-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06864403

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06864403, "Mirikizumab in the Treatment of Chronic Inflammatory Conditions of the Pouch". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT06864403. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*